First-line single-agent panitumumab in frail elderly patients with wild-type RAS unresectable colorectal cancer: a phase II study protocol OGSG 1602
Abstract Background A cytotoxic chemotherapeutic regimen is not routinely recommended for frail elderly patients with unresectable colorectal cancer (CRC) because of susceptibility to treatment. Panitumumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR). Use of panitu...
Main Authors: | Tetsuji Terazawa, Takeshi Kato, Masahiro Goto, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Yoshihiro Matsubara, Taroh Satoh |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-06-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-019-5821-z |
Similar Items
-
LM02 trial Perioperative treatment with panitumumab and FOLFIRI in patients with wild-type RAS, potentially resectable colorectal cancer liver metastases—a phase II study
by: Gudrun Piringer, et al.
Published: (2023-08-01) -
PRIDE syndrome associated with panitumumab treatment –
case report and literature review
by: Magalena Pałdyna, et al.
Published: (2023-05-01) -
Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01) -
Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy
by: Toshifumi Yamaguchi, et al.
Published: (2022-07-01) -
Pathologic complete response in metastatic right-sided colon cancer treated with panitumumab and FOLFOX4 chemotherapy regimen
by: Džunić Miljana, et al.
Published: (2022-01-01)